Onconova Announces Five Presentations on Rigosertib in Myelodysplastic Syndromes (MDS) at the ASH 2019 Annual Meeting & Exposition

November 7, 2019

- Oral presentation will feature efficacy and safety data from Expanded Phase 2 Trial of oral rigosertib in combination with azacitidine

- Four poster presentations to feature:
  - biomarker genomic studies from pivotal INSPIRE Trial
  - a novel adaptive trial design for a pivotal Phase 3 Study
  - trial design options for future combination study in first line higher risk MDS
  - Influence of rigosertib/azacitidine combination on key pathways involved in in-vitro hematopoiesis

NEWTOWN, Pa., Nov. 07, 2019 (GLOBE NEWSWIRE) -- Onconova Therapeutics, Inc. (NASDAQ: ONTX), a Phase 3 stage biopharmaceutical company discovering and developing novel products to treat cancer, with a focus on Myelodysplastic Syndromes (MDS), today announced that five abstracts relating to the Company’s lead product candidate, rigosertib, were accepted for presentation at the 61st American Society of Hematology (ASH) Annual Meeting & Exposition in Orlando, FL, which takes place December 7-10, 2019.

Oral Presentation:

1. **Phase II Study of Oral Rigosertib Combined with Azacitidine (AZA) As First Line Therapy in Patients (Pts) with Higher-Risk Myelodysplastic Syndromes (HR-MDS)**
   - **Session Name:** 637. Myelodysplastic Syndromes – Clinical Studies: Combination Therapies
   - **Abstract:** 566
   - **Date:** Monday, December 9, 2019
   - **Presentation Time:** 7:00 AM - 8:30 AM
   - **Location:** W311 EFGH (Orange County Convention Center)
   - **Presenter:** Shyamala C. Navada, MD, Division of Hematology/Oncology, Icahn School of Medicine at Mount Sinai, New York, NY

Poster Presentations:

2. **Genomic Profiling in Patients with Higher-Risk Myelodysplastic Syndrome (HR-MDS) Following HMA Failure: Baseline Results from the INSPIRE Study (04-30)**
   - **Session Name:** 637. Myelodysplastic Syndromes – Clinical Studies: Poster II
   - **Abstract:** 3015
   - **Date:** Sunday, December 8, 2019
   - **Session Time:** 6:00 PM – 8:00 PM
   - **Location:** Hall B (Orange County Convention Center)
   - **Presenter:** Guillermo Garcia-Manero, MD, Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX

3. **The INSPIRE Study in Higher-Risk Myelodysplastic Syndrome (HR-MDS): A Novel Phase 3 Study Adaptive Design for Hematological Malignancies in Adults**
   - **Session Name:** 637. Myelodysplastic Syndromes – Clinical Studies: Poster III
   - **Abstract:** 4249
   - **Date:** Monday, December 9, 2019
   - **Presentation Time:** 6:00 PM - 8:00 PM
   - **Location:** Hall B (Orange County Convention Center)
   - **Presenter:** Anna Jonasova, MD, General University Hospital in Prague, 1st Internal Clinic - Clinic of Hematology, Prague, Czech Republic

   - **Session Name:** 637. Myelodysplastic Syndromes – Clinical Studies: Poster III
   - **Abstract:** 4268
   - **Date:** Monday, December 9, 2019
   - **Session Time:** 6:00 PM – 8:00 PM
About Oral Rigosertib

The oral form of rigosertib was developed to provide a potentially more convenient dosage form for use where the duration of treatment may extend to multiple years. This dosage form may also support combination therapy modalities. To date, over 400 patients have been dosed with the oral formulation of rigosertib in clinical trials. Combination therapy of oral rigosertib with azacitidine, the standard of care in HR-MDS, has also been studied. Currently, oral rigosertib is being developed as a combination therapy together with azacitidine for patients with higher-risk MDS who require HMA therapy. A Phase 1/2 trial of the combination therapy has been fully enrolled, and the preliminary efficacy and safety data was presented at The American Society of Hematology (ASH) Annual Meeting in December 2018 and will be updated at the upcoming ASH Meeting in December 2019.

Forward-Looking Statements

Some of the statements in this release are forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, Section 21E of the Securities Exchange Act of 1934, as amended, and the Private Securities Litigation Reform Act of 1995, and involve risks and uncertainties. These statements relate to Onconova expectations regarding the INSPIRE Trial and Onconova’s other development plans. Onconova has attempted to identify forward-looking statements by terminology including “believes,” “estimates,” “anticipates,” “expects,” “plans,” “intends,” “may,” “could,” “might,” “will,” “should,” “approximately” or other words that convey uncertainty of future events or outcomes. Although Onconova believes that the expectations reflected in such forward-looking statements are reasonable as of the date made, expectations may prove to have been materially different from the results expressed or implied by such forward-looking statements. These statements are only predictions and involve known and unknown risks, uncertainties, and other factors, including Onconova’s ability to continue as a going concern, the need for additional financing, the outcome of Onconova’s pending litigation, Onconova’s ability to continue as a going concern, the need for additional financing, the outcome of Onconova’s pending litigation, and other factors. These forward-looking statements are based on information available at the time and Onconova assumes no obligation to update these forward-looking statements as conditions change.
financing, the success and timing of Onconova's clinical trials and regulatory approval of protocols, our collaborations, and those discussed under the heading "Risk Factors" in Onconova's most recent Annual Report on Form 10-K and quarterly reports on Form 10-Q. Any forward-looking statements contained in this release speak only as of its date. Onconova undertakes no obligation to update any forward-looking statements contained in this release to reflect events or circumstances occurring after its date or to reflect the occurrence of unanticipated events.

**General Contact**

Avi Oler  
Onconova Therapeutics, Inc.  
267-759-3680  
ir@onconova.us  
http://www.onconova.com/contact/